Inflammation during acute coronary syndromes - Risk of cardiovascular events and bleeding - Articles - Cardiovascular

Heart, Artery and Coronary Diseases

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial

JAMA.

Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon H, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, TICO Investigators.

doi: 10.1001/jama.2020.7580.

Heart, Artery and Coronary DiseasesMyocardial InfarctionThrombosis and Stroke

Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome

J Am Coll Cardiol.

Gibson CM, Levitan B, Gibson WJ, Yee MK, Murphy SA, Yuan Z, Chakrabarti AK, Lee M, Braunwald E

doi: 10.1016/j.jacc.2018.04.055.

Cardiovascular Risk and Diseases

Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial

JAMA Cardiol.

Mani P, Puri R, Schwartz GG, Nissen SE, Shao M, Kastelein JJP, Menon V, Lincoff AM, Nicholls SJ

doi: 10.1001/jamacardio.

RECOMMENDED

Lipid-Lowering Drugs

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

J Am Coll Cardiol.

Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG, ODYSSEY OUTCOMES Committees and Investigators.

doi: 10.1016/j.jacc.2019.10.057.

Heart, Artery and Coronary DiseasesTherapy and Intervention

Impact of renal dysfunction and acute kidney injury on outcome in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention

Eur Heart J Acute Cardiovasc Care.

De Rosa R, Morici N, De Servi S, De Luca G, Galasso G, Piscione F, Ferri LA, Piatti L, Grosseto D, Tortorella G, Franco N, Lenatti L, Misuraca L, Leuzzi C, Verdoia M, Sganzerla P, Cacucci M, Ferrario M, Murena E, Sibilio G, Toso A, Savonitto S

doi: 10.1177/2048872620920475.

Heart, Artery and Coronary DiseasesHeart FailureHypertensionMyocardial InfarctionThrombosis and Stroke

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial

JAMA Cardiol.

Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K, Kuder JF, Braunwald E, Sabatine MS, O'Donoghue ML

doi: 10.1001/jamacardio.

Cardiovascular Risk and Diseases

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial

JAMA.

Ray KK, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG, BETonMACE Investigators and Committees.

doi: 10.1001/jama.2020.3308.

Heart, Artery and Coronary DiseasesThrombosis and StrokeTherapy and Intervention

Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study

Eur Heart J.

Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G, Fourcade L, Mouret JP, Lambert M, Verdier V, Morange PE, Alessi MC, Bonnet JL

doi: 10.1093/eurheartj/ehx175.

RECOMMENDED

Lipid-Lowering Drugs

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

N Engl J Med.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators

doi: 10.1056/NEJMoa1801174.

Related content